Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?

Jabbour, Elias; Cortes, Jorge E.; Kantarjian, Hagop M.
February 2009
Mayo Clinic Proceedings;Feb2009, Vol. 84 Issue 2, p161
Academic Journal
Treatment responses to imatinib vary among patients with chronic myeloid leukemia (CML), and definitions of treatment failure and suboptimal response have been published. This article discusses monitoring and treatment of patients with CML after failure of or suboptimal response to imatinib therapy. We reviewed articles listed on PubMed from January 1, 2002, to July 31, 2008, and abstracts from the 2007 Annual Meeting of the American Society of Hematology. Search terms used were chronic myeloid/myelogenous leukemia, imatinib, and BCR-ABL. To enable early recognition of suboptimal responses, patients should be frequently monitored according to published guidelines, including cytogenetic analysis every 6 months until a complete response is achieved and molecular monitoring every 3 months from the start of therapy or monthly if an increasing BCR-ABL1 transcript level is detected. Mutational analysis of BCR-ABL1 may assist with treatment selection. A recent survey suggests that a notable proportion of physicians do not follow treatment guidelines and that broader communication is required. Recent recommendations state that, in patients whose response to Imatinib at 400 mg/d is suboptimal, the dose should be increased, whereas alternative therapies, such as dasatinib, nilotinib, and aliogeneic stem cell transplant (in eligible patients), and imatinib dose escalation should be considered after imatinib failure. However, clinical data are lacking to confirm this sequence of treatments, and introducing alternative therapies at an earlier stage of treatment, for example, after a suboptimal response, may produce better long-term outcomes in a higher proportion of patients. Patient and disease characteristics should be carefully considered to optimize treatment strategy for CML.


Related Articles

  • Chronic Myelocytic Leukemia -- Part II: Approaches to and Molecular Monitoring of Therapy. Randolph, Tim R. // Clinical Laboratory Science;Winter2005, Vol. 18 Issue 1, p49 

    Focuses on a study which presented the approaches to and molecular monitoring of therapy for chronic myelocytic leukemia (CML). Evolution of the therapeutic approaches for the disease; Effectiveness of the Imatinib therapy as measured by molecular methods; Strategies for the management of CML...

  • What role does imatinib play in CML after the approval of dasatinib and nilotinib for newly diagnosed CML? Talpaz, Moshe; Deininger, Michael // Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p11 

    The article presents the views of U.S. medical experts Moshe Talpaz and Michael Deininger on the role that imatinib and nilotinib play in the treatment of newly diagnosed chronic myelogenous leukemia (CML).

  • Dasatinib in the Treatment of Chronic Myeloid Leukemia. Gora-Tybor, Joanna; Robak, Tadeusz // Current Signal Transduction Therapy;Jan2011, Vol. 6 Issue 1, p99 

    The recognition that the BCR-ABL gene and corresponding protein with deregulated tyrosine kinase (TK) activity is crucial for malignant transformation in chronic myeloid leukemia (CML), led to the synthesis of the small-molecule drugs designed to interfere with BCR-ABL TK activation. The first...

  • Comparison of long-term outcome of early versus late chronic phase imatinib receivers. Gürkan, Emel; Paydaş, Semra // Journal of Hematological Malignancies;Sep2012, Vol. 2 Issue 3, p8 

    The introduction of imatinib mesylate made a remarkable contribution to the management of patients with chronic myeloid leukemia. In this study, we assessed the long-term efficacy of imatinib exposure in patients with CML in chronic phase according to European recommendations which consists both...

  • Delivery of two normal twins exposed to imatinib and nilotinib during the first trimester of pregnancy in a woman with chronic myeloid leukemia. Mseddi, S. Hadiji; Kallel, F.; Amouri, H.; Affes, H.; Mdhaffar, M.; Elloumi, M. // Journal of Hematological Malignancies;Sep2012, Vol. 2 Issue 3, p74 

    We report here the case of a 35-year-old woman. She was diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia. Because of primary infertility, she received imatinib without contraception. Complete cytogenetic response was not obtained with 800 mg/day. As a result, the patient...

  • Imatinib gives impressive long-term survival in CML patients.  // British Journal of Hospital Medicine (17508460);Feb2009, Vol. 70 Issue 2, p71 

    The article reports on the "International Randomized Interferon VersusSTI571," (IRIS) study done to test the effectiveness of Glivec (imatinib) in the treatment of Philadelphia chromosome positive (Ph+) chronic myeloid Leukaemia (CML). The study states that, 86% of patients suffering from the...

  • Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia. Yaoyu Chen; Cong Peng; Con Sullivan; Dongguang Li; Shaoguang Li // Anti-Cancer Agents in Medicinal Chemistry;2010, Vol. 10 Issue 2, p111 

    Chronic myeloid leukemia (CML) is induced by the BCR-ABL oncogene, a product of Philadelphia (Ph) chromosome. The BCR-ABL kinase inhibitor imatinib is a standard treatment for Ph+ leukemia, and has been shown to induce a complete hematologic and cytogenetic response in most chronic phrase CML...

  • Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy. Pytel, Dariusz; Sliwinski, Tomasz; Poplawski, Tomasz; Ferriola, Deborah; Majsterek, Ireneusz // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 1, p66 

    Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the...

  • CML Patients Taking Imatinib Have Similar Mortality Rates to People in General Population.  // JNCI: Journal of the National Cancer Institute;Apr2011, Vol. 103 Issue 7, pNP 

    The article discusses a study published online March 22, 2011 in the "Journal of the National Cancer Institute" which shows that patients taking imatinib (Gleevec) for chronic myelogenous leukemia (CML) have a mortality rate similar to that of the general population. The study, known as the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics